Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02946164
Other study ID # R34MH106359
Secondary ID
Status Completed
Phase N/A
First received October 25, 2016
Last updated February 20, 2018
Start date October 2016
Est. completion date December 31, 2017

Study information

Verified date February 2018
Source University of California, Berkeley
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a pilot evaluation of 'Stick To It', a behavioral intervention based on the concept of gamification. The objective of the program is to encourage young men who have sex with men (MSM) to be regularly screened for HIV and sexually transmitted infections (STIs) and to adopt safer sexual behaviors, with the ultimate goal to decrease HIV and STI incidence. Gamification is the application of game elements, like points, badges, and rewards, to non-game settings.


Description:

The investigators will conduct a quasi-experimental pilot study of 'Stick To It', a prevention intervention that uses gamification principles and mechanics. The intervention includes an online timer that reminds men to get tested, online quizzes, and peer recruitment; these activities are awarded with points redeemable for chances at prizes at participating clinics. The intervention was designed based on findings from interviews with health staff and focus groups with young MSM, and with input from a gamification consultant. The primary hypothesis is that the intervention will increase repeat HIV/STI testing among young MSM. The intervention will be implemented at two STI clinics in Oakland and Los Angeles, California in 2-week intervals for six months. The investigators will review medical records of exposed and unexposed young MSM attending the same STI clinics to compare uptake of quarterly HIV testing and self-reported behavior after six months.


Recruitment information / eligibility

Status Completed
Enrollment 166
Est. completion date December 31, 2017
Est. primary completion date October 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 26 Years
Eligibility Inclusion Criteria:

- 18-26 years of age

- male

- self-identify as gay / bisexual / queer

- willing and able to provide informed consent to join the Stick To It program

- resident in one of several zip code areas surrounding the clinic

Exclusion Criteria:

- Not a resident of one of included zip code areas

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Stick To It
The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.

Locations

Country Name City State
United States AHF Hollywood Wellness Center Los Angeles California
United States AHF Wellness Center Oakland Oakland California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Berkeley AIDS Healthcare Foundation, University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Repeat HIV Testing The number of men in the intervention who receive =1 additional HIV tests over 6 months of follow-up 6 months
Secondary HIV-related risk behavior We will determine the number of reported sex partners, the prevalence and frequency of unprotected anal intercourse with a partner of opposite or unknown status in the past 6 months 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2

External Links